vonapanitase

DRUG3 trials

Sponsors

Proteon Therapeutics

Conditions

Chronic Kidney DiseasePeripheral Artery Disease

Phase 1

Safety/ Feasibility of Percutaneous Administration of Vonapanitase as Monotherapy for Peripheral Artery Disease (PAD) of the SFA and Popliteal Arteries

WithdrawnNCT02953496

Proteon TherapeuticsPeripheral Artery Disease

End: 2019-04-30Updated: 2019-05-02

Safety/Feasibility of Vonapanitase Following Angioplasty for Patients With Peripheral Artery Disease (PAD) Below the Knee (BTK)

CompletedNCT02956993

Proteon TherapeuticsPeripheral Artery Disease

Start: 2016-11-30End: 2019-04-30Updated: 2019-05-02

Phase 3

A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)

CompletedNCT02414841

Proteon TherapeuticsChronic Kidney Disease

Start: 2015-08-31End: 2019-05-01Updated: 2019-08-13

Related Papers

Evaluating the effectiveness of systemic heparin during arteriovenous fistula creation by emulating a target trial.

2025-03-013 citations

Evaluating national guideline concordance of recurrent interventions after radiocephalic arteriovenous fistula creation.

2022-12-2212 citations

PATENCY-2 trial of vonapanitase to promote radiocephalic fistula use for hemodialysis and secondary patency

The Journal of Vascular Access2021-01-2224 citations

Challenges in Developing New Therapies for Vascular Access Dysfunction

Clinical Journal of the American Society of Nephrology2017-09-118 citations